IDEXX Laboratories Reports Strong Q1 2026 Performance with Revenue Growth and Strategic Momentum
IDEXX Laboratories reported strong organic revenue growth of 11% in Q1 2026, driven by robust performance across its Companion Animal Group and international markets. The company raised full-year guidance to a range of 7.7% to 9.7%, citing improved execution and sector outlook.
Tickers: $IDXX
Topics: diagnostics international_expansion operating_margin revenue_growth